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Abstract
New Delhi metallo-beta-lactamase (NDM-1) is an enzyme that makes bacteria resistant to a broad range of beta-lactam
antibiotic drugs. This is because it can inactivate most beta-lactam antibiotic drugs by hydrolyzing them. For in-depth
understanding of the hydrolysis mechanism, the three-dimensional structure of NDM-1 was developed. With such a structural
frame, two enzyme-ligand complexes were derived by respectively docking Imipenem and Meropenem (two typical beta-
lactam antibiotic drugs) to the NDM-1 receptor. It was revealed from the NDM-1/Imipenem complex that the antibiotic drug
was hydrolyzed while sitting in a binding pocket of NDM-1 formed by nine residues. And for the case of NDM-1/Meropenem
complex, the antibiotic drug was hydrolyzed in a binding pocket formed by twelve residues. All these constituent residues of
the two binding pockets were explicitly defined and graphically labeled. It is anticipated that the findings reported here may
provide useful insights for developing new antibiotic drugs to overcome the resistance problem.
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Introduction
The rapid growth of antibiotic resistance has become a main
clinical and epidemiological problem for human health [1]. In
bacteria, b-lactam antibiotics are primarily hydrolyzed by b-
lactamases in an acylation-deacylation-based process [2]. Thus, it
is believed that b-lactamases play an important role in leading to
resistance of bacteria to b-lactam antibiotics. These enzymes are
capable of cleaving the amide bond of the b-lactam ring so as to
inactivate the b-lactam antibiotic drugs. According to their
sequence similarities, b-lactamases can be generally divided into
four classes, named as A, B, C, and D. Classes A, C, and D of b-
lactamases contain serine groups in their active sites, while the
enzymes in class B are metalloproteins, or called ‘‘metallo-b-
lactamases’’, that require one or two zinc ions for their activity.
Among all the b-lactamases, metallo- b-lactamases are the major
culprit causing bacteria to resist antibiotics, due to the reason that
they can degrade all b-lactams except monobactams and that they
are special for their constant and efficient carbapenemase activity
[3].
In December 2009 a novel metallo-b-lactamase was identified
in a patient hospitalized in New Delhi with an infection caused by
klebsiella pneumonia [4]. This b-lactamase was later detected in
bacteria in India, Pakistan, United Kingdom, United States, and
Canada. The New Delhi metallo-b-lactamase (NDM-1) has the
ability to make bacteria resistant to a wide range of b-lactam
antibiotics, including the carbapenem family antibiotics that are a
mainstay for the treatment of antibiotic-resistant bacterial
infections [5,6]. According to the report of the United Kingdom’s
Health Protection Agency, most isolates with NDM-1 are resistant
to all standard intravenous antibiotics for the treatment of severe
infections. The most common bacteria that make this enzyme are
Gram negative such as Escherichia coli and Klebsiella pneumonia,
but the gene for NDM-1 can spread from one strain of bacteria to
another by horizontal gene transfer.
To reveal the resistance mechanism of bacteria to b-lactam
antibiotics due to the existence of NDM-1, an indispensable
knowledge is of the 3D (three-dimensional) structure of NDM-1.
Since so far no 3D structure whatsoever has been determined by
experiments for NDM-1, we have to resort to the approach of
structural bioinformatics [7]. Recently, growing evidences have
indicated that various tools in structural bioinformatics, such as
homology modeling [8,9,10,11,12,13,14,15,16], molecular dock-
ing [17,18,19,20,21,22], as well as molecular dynamics simulations
[23,24,25,26,27,28,29,30,31], can timely provide very useful
information and insights for biomedical science and drug
development and hence are quite rewarding [14,22,29,32,33,
34,35,36,37,38,39]. In view of this, the present study was initiated
in an attempt to develop a homology model for NDM-1, based on
which the molecular docking operations and molecular dynamics
simulations were performed in hopes that the information thus
obtained may provide useful insights or clues for designing new
drugs to overcome the antibiotic resistance problem.
Materials and Methods
The entire sequence of NDM-1, which contains 158 amino
acids, was taken from NCBI Protein database with an accession of
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structure of VIM-2, a Zn-b-lactamase from Pseudomonas
aeruginosa [40], was selected as a structural template to perform
homology modeling to develop the 3D structure of NDM-1. The
PDB code of the crystal structure is 1ko3, which was released in
2008 with a resolution of 2.20 A ˚ [40]. The entire sequence of 1ko3
contains 230 amino acids. The sequence alignment between
NDM-1 and 1ko3 was performed by the Molecular Operating
Environment (MOE), and the alignment result thus obtained
indicates that the two proteins have a sequence identity of 43%.
Meanwhile, using the web-server EzyPred [41] at http://www.
csbio.sjtu.edu.cn/bioinf/EzyPred/ and the protein sequence
information, it was identified that NDM-1 is a member of
hydrolases enzyme family (acting on carbon-nitrogen bonds other
than peptide bonds), and so is 1ko3. Since both NDM-1 and 1ko3
belong to a same enzyme family with the same action mechanism,
and their sequence identity is higher than 40%, it is quite
reasonable to use the crystal structure of 1ko3 [40] as a template to
develop the 3D structure of NDM-1 via homology modeling.
Based on the sequence alignment (Fig. 1) as well as the atomic
coordinates of 1ko3, the 3D structure of NDM-1 was derived by
using the I-TASSER algorithm, an extension of the previous
TASSER (Threading/Assembly/Refinement) method [42,43,44].
The homolog-modeled 3D structure was subject to a short-time
molecular dynamics simulation (,3 ns) for further refinement.
The final 3D structure thus obtained for NDM-1 is shown in Fig. 2.
Meanwhile, some assessments by the Swiss Model Server indicated
that the computed structure is quite reasonable and creditable.
Subsequently, molecular docking operations were carried out
with Monte Carlo simulated annealing [45] to get the favorable
binding interaction modes for NDM-1 respectively with Imipenem
and Meropenem, two typical b-lactam antibiotic drugs. It was
reported recently [6] that NDM-1 showed a comparatively high
resistance to Imipenem and Meropenem. The binding pocket was
identified using Q-SiteFinder [46]. Because binding of inhibitors in
the active site may induce a conformational change to closing
some flaps [47], we adopted a flexible docking procedure to
construct the binding modes of NDM-1 with Imipenem and
Meropenem. Before the docking procedure, we extracted 1000
conformations of NDM-1 from the aforementioned 3-ns molecular
dynamics simulation. The ligand (Imipenem or Meropenem) was
then docked to all of these conformations to search for a favorable
binding mode. The docking program [48] used in this study would
automatically generate a diversified set of configurations by
randomly changing the ligand’s coordinates. When a new
configuration of the ligand was generated, the search for the
Figure 1. The sequence alignment of NDM-1 (chain-1) with 1ko3.pdb (chain-2); shown in the lower panel are the chemical
structures of Imipenem and Meropenem. The amino acids in this figure are colored according to the following four types: (1) acidic, red; (2)
basic, dark blue; (3) hydrophobic, green; (4) hydrophilic, light blue. The sequence identity of the two proteins is about 43%.
doi:10.1371/journal.pone.0018414.g001
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simulated annealing to optimize the purely spatial contacts as well
as electrostatic interactions. Finally, the favorable binding mode
thus obtained was further optimized by a short time molecular
dynamics simulation (,5 ns). The binding energy was calculated
using a scoring function London dG [49,50,51]. In all our
calculations, the Merck force field (FFMM94) parameters were
adopted. The most favorable binding interactions thus obtained
for NDM-1 with Imipenem and Meropenem are given in Fig. 3
and Fig. 4, respectively.
Results and Discussion
Homology-Modeled 3D Structure of NDM-1
A total of 100 homology-modeled structures for NDM-1 were
derived with each having a C-score. The C-score is a ‘‘confidence
score’’ for estimating the quality of a computed model: a high C-
score signifies a model with a high confidence and vice-versa.
Shown in Fig. 2A is the structure with the highest C-score that was
used as a receptor for further docking studies. Meanwhile, we
employed PROCHECK [52] to estimate the quality of our
models. It was indicated by PROCHECK that there are 93.1%
residues located in the ‘‘core’’ and ‘‘allowed’’ regions, 4.6% in the
‘‘general’’ region and only 2.3% in the ‘‘disallowed’’ regions (Fig.
S1). In the computational structure, all the bond lengths for the
main-chain residues and 91.9% bond angles for the main-chain
residues are within the allowed limits. To further examine our
computational model of NDM-1, we also used the tool of
QMEAN, which is a scoring function of a linear combination of
6 structural descriptors [53]. The QMEAN score ranges between
0 and 1 with higher value to reflect a better quality of the model.
The QMEAN score for the current computational model is 0.67,
and the density plot of this QMEAN score is shown in Fig. S2. To
evaluate the absolute model quality, we also calculated a Z-score
of the computational model in comparison with the scores of the
reference X-ray structures of similar size from the Protein Data
Bank (Fig. S3). For each of the QMEAN components, a Z-score
was computed in comparison with the average X-ray structures
(the average value is 0, as shown in Fig. S4). Based on these
analyses, we further examined the per-residue error (Fig. S5),
visualized using a color gradient from blue (reliable regions with
estimated error below 1 A ˚) to red (potentially unreliable regions
with estimated error above 3.5 A ˚). We found that the residues in
the potentially unreliable regions were mainly located on the loop
regions in the computational model, indicating that further
molecular dynamics optimizations are needed, as described below.
However, after a 3-ns molecular dynamics simulation, all the
residues in our model were in the ‘‘core’’ and ‘‘allowed’’ regions. It
can be seen from Fig. 2A that, like most of the other metallo-b-
lactamases, the NDM-1 protein belongs to the a/b structural class
[54], with 3 helices and 7 b-strands. The 3 helices were exposed to
the solvent. The N-terminal and C-terminal regions of NDM-1
can be superposed by a 180 degrees rotation around a central axis,
indicating that the entire structure may have arisen from the
duplication of a gene. It was found after superposing NDM-1 to its
Figure 2. Illustration to show (A) the computed 3D structure of
NDM-1 that contains three helices and 7 b-strands, and (B) a
superimposition of the homology modeled NDM-1 structure
(red) with its template 1ko3 (yellow).
doi:10.1371/journal.pone.0018414.g002
Figure 3. A close view to show (A) the zinc coordinates, (B)
binding pocket of NDM-1 for the antibiotic drug Imipenem,
and (C) binding pocket of NDM-1 for the antibiotic drug
Meropenem. The binding pocket is formed by those residues that
have at least one heavy atom with a distance within 5 A ˚ [51] to
Imipenem/Meropenem.
doi:10.1371/journal.pone.0018414.g003
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similar backbone (Fig. 2B) owe to their high sequence identity
percentage. However, some a-helices and b-strands in 1ko3.pdb
are not seen in the NDM-1 model because 1ko3.pdb contains 5
helices and 11 b-strands. This is due to the sequence deletion of
NDM-1 in its C-terminal and N-terminal regions. It is instructive
to note that such sequence deletion might make the b-lactam
antibiotic drugs easier to access the binding pocket of NDM-1.
Similar with other metallo-b-lactamases, the active site of
NDM-1 presents two metal ion binding sites: His site and Cys site.
Thus, two zinc ions can be detected in our homology model at
both the His and Cys sites with a distance of 4.20 A ˚ apart.
According to some experimental data, the one located in the His
site has a higher occupancy (1.3 fold) than that in the Cys site
(Fig. 3A). The zinc ion in the His site possesses a tetrahedral
coordination sphere and is coordinated by His56, His58, and
His125. The other zinc ion in the Cys site has a trigonal-pyramidal
coordination sphere that involves Ser11, Asp60, and Cys144.
Binding Modes of Inactivating Antibiotic Drugs
Since metallo-b-lactamases can inactivate the b-lactam antibi-
otic drugs by cleaving the amide (carbon-nitrogen) bond of the b-
lactam ring [2], it can provide us very useful insights about the
essence of the drug resistance problem by analyzing the binding
interaction modes obtained by docking Imipenem and Merope-
nem to NDM-1 receptor, respectively.
Shown in Fig. 3B is a close view of the binding interactions
obtained by docking the antibiotic drug Imipenem to the receptor
NDM-1. Its binding pocket is formed by nine residues that have at
least one heavy atom with a distance within 5 A ˚ [55] to Imipenem,
as labeled in Fig. 3B. Interestingly, the constituent residues thus
defined for the binding pocket are quite consistent those identified
by the online web-server tool Q-SiteFinder for forming the
extended cleft active site of NDM-1. In the NDM-1/Imipenem
complex, Met3 and Phe6 are located on the brink of the active site,
providing some van der Waals interactions to the drug molecule. It
can be seen from Fig. 3B that, in addition to the van der Waals
interaction of the Imipenem drug with the surrounding binding
pocket residues, there are remarkable hydrogen bonds that have
tightly tethered the drug to Glu88 and Thr126 of the receptor,
making NDM-1 able to recognize the antibiotic drug followed by
cleaving the amide bond of its b-lactam ring so as to inactivate
Imipenem. The detailed information for these hydrogen bonds is
listed in Table 1.
For the case of Meropenem, it can interact with almost the same
residues as Imipenem. As can be seen from Fig. 3C, the binding
pocket for Meropenem involves six residues, of which Glu88 and
Thr126 form three hydrogen bonds with the antibiotic drug. Since
there is one more five-member ring in Meropenem (Fig. 3C), some
additional hydrogen bonds are needed to stabilize the ligand
during the process of cleaving its amide bond and inactivate the
antibiotic drug. Based on these structural findings and previous
theoretical studies [56,57,58], we proposed a catalytic mechanism
for NDM-1, as illustrated in Fig. 4. In our model, the metal-
binding Asp60 acts as the general base that activates the water
nucleophile, while the protonation of Asp60 results in the cleavage
of its bond to the metal ion.
Supporting Information
Figure S1 Ramachandran plot for the computational model of
NDM-1 by PROCHECK.
(TIF)
Figure S2 The density plot of the QMEAN score for the
computational model of NDM-1.
(TIF)
Figure S3 Estimated absolute model quality by the comparison
of the QMEAN scores with the reference x-ray structures in the
Protein Data Bank.
(TIF)
Figure 4. The proposed mechanism for the initial ring-opening step in the antibiotic catalysis of NDM-1, where ES, TS, and EI
represent enzyme-substrate, transition state, and enzyme intermediate, respectively.
doi:10.1371/journal.pone.0018414.g004
Table 1. Detailed information for the H bonding formed by
NDM-1 and antibiotic drugs.
H – donor H – receptor Bond distance (A ˚) Lifetime (%)
Glu88 (Ob) Imipenem (NH2) 2.89 43.8
Glu88 (Ob) Meropenem (NH2) 3.01 39.1
Thr126 (Oa) Imipenem (NH2) 3.04 19.8
Thr126 (Oa) Meropenem (NH2) 2.78 45.4
doi:10.1371/journal.pone.0018414.t001
Molecular Modeling of NDM-1
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the Z-score of each component in comparison with the average x-
ray structures.
(TIF)
Figure S5 Per-residue error visualized by using a color gradient
from blue (reliable region, estimated error below 1 A ˚) to red
(potentially unreliable regions, estimated error above 3.5 A ˚).
(TIF)
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